IDIA Idorsia Ltd

4.445USD3.746 CHF · SWX-2.45%Mkt Cap: 1.20B USDP/E: —

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.20B USD
Enterprise Value2.68B USD
Revenue (TTM)261.23M USD
Gross Profit236.94M USD
Net Income (TTM)-132.54M USD
Revenue/Share1.02 USD
Last Price4.445 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees424
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0363463438
Valuation
P/E (Trailing)—
P/E (Forward)67.72
PEG—
EV/EBITDA-16.68
EV/Revenue10.24
P/S4.59
P/B-0.82
EPS (TTM)-1.36 USD
EPS (Forward)0.07 USD
52W Range
3.31720% of range8.971
52W High8.971 USD
52W Low3.317 USD
Profitability
Gross Margin90.52%
Oper. Margin-68.38%
EBITDA Margin-61.39%
Profit Margin-50.64%
ROE9.82%
ROA-23.98%
ROIC-272.38%
ROCE-38.16%
Growth
Revenue Growth49.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-181.82M USD
CapEx (TTM)16.40M USD
FCF Margin-31.49%
FCF Yield-6.86%
Net Debt1.48B USD
Net Debt/EBITDA-9.21
Net Debt/FCF—
Balance Sheet
Debt/Equity-1.11
Current Ratio0.58
Quick Ratio0.38
Book Value/Sh-5.42 USD
Cash/Share0.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2017
Pay DateOct 13, 2020
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.933 USD
Upside (mean)+33.5%
Target Range5.340 USD – 7.120 USD
5.340+33.5% to mean7.120
# Analysts3
Ownership
Shares Out.269.78M
Float155.70M
Insiders30.19%
Institutions36.65%
Technical
SMA 505.200 (-14.5%)
SMA 2005.481 (-18.9%)
Beta1.68
S&P 52W Chg12.00%
Avg Vol (30d)782.75K
Avg Vol (10d)808.82K
Technical Indicators
RSI (14)33.0
MACD-0.1599
MACD Signal-0.1294
MACD Hist.-0.0305
BB Upper5.566 USD
BB Middle4.964 USD
BB Lower4.362 USD
BB Width24.25%
ATR (14)0.2307 USD
Vol Ratio (20d)0.69x

About Idorsia (SWX: IDIA)

›

Idorsia (SWX: IDIA) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 424 employees.

The shares were at 3.746 CHF on 19 November 2026, up 19.1% over 52 weeks. Its 52-week range is 2.795 CHF to 7.560 CHF: the price is 50.4% below the high and 34.0% above the low.

Its market capitalisation is 1.01B CHF.

Idorsia reports return on equity of 9.8%, an operating margin of -68.4% and revenue up 49.3% year over year.

Its debt exceeds its cash by 1.24B CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 5.000 CHF is 33.5% above the current price. The next earnings report is expected on 25 February 2027.